BALA CYNWYD, PA — Larimar Therapeutics, Inc. has begun a rolling application for accelerated U.S. approval of its experimental Friedreich’s ataxia treatment, positioning the biotechnology company to potentially launch the …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.